Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Adial Pharmaceuticals Inc ADIL

Healthcare Biotechnology
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid... see more

Current News (NDAQ:ADIL)

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

GlobeNewswire 11 days ago

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

GlobeNewswire 12 days ago

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

GlobeNewswire January 14, 2026

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds

GlobeNewswire November 26, 2025

Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 14, 2025

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

GlobeNewswire October 17, 2025

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

GlobeNewswire October 9, 2025

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

GlobeNewswire September 16, 2025

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

GlobeNewswire September 3, 2025
View More News ››

Opinion & Analysis (NDAQ:ADIL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ADIL)

ADIL....for all u swill hounds out there

On watch ....News
Iseneschal - January 29, 2025

BUY BUY BUY BUY BUY

Told ya
Nibinator - July 31, 2024

BUY BUY BUY BUY BUY

Will pop to 3$
Nibinator - July 23, 2024

RE:RE:ADIL...early a.m runner on watch after NR

Now at $1.86....Cheers !
Iseneschal - April 10, 2024

RE:ADIL...early a.m runner on watch after NR

Now at $1.91
Iseneschal - April 10, 2024

ADIL...early a.m runner on watch after NR

Don't get married to this....JMHO Already ran weeks ago ; ) Currently at $2.49
Iseneschal - April 10, 2024
View more Bullboard ››

Spanish Mountain Gold Ltd.

Spanish Mountain Gold Ltd.

Spanish Mountain Gold Ltd., an exploration and development stage company, engages in the acquisition, exploration, and ...
View More »

Podcasts